Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 18, 2026

Verismo Licenses Stanford PACK-IT Tech for In Vivo KIR-CAR T Therapies

Listen
0:00 / 0:00

Key Takeaways

  • Stanford’s PACK-IT enables targeted lentiviral CAR gene delivery to T cells in vivo or via accelerated ex vivo workflows, using engineered envelope proteins and antibody-directed receptor binding for viral entry.
  • In vivo CAR T engineering aims to reduce manufacturing time, cost, and access constraints versus autologous ex vivo CAR-T, potentially compressing a weeks-long process into a same-day dosing step.
SHOW MORE

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Verismo Therapeutics announced on November 18, 2026, that it has licensed the programmable antigen-mediated cellular knock-in of T cell (PACK-IT) in vivo chimeric antigen receptor T cell (CAR T) engineering technology from Stanford Medicine. The company plans to apply the technology to its multi-chain killer cell immunoglobulin-like receptor (KIR)-CAR platform to develop off-the-shelf in vivo oncology candidates.¹ The technology comes from the laboratory of Crystal Mackall, MD, Ernest and Amelia Gallo Family professor and professor of pediatrics and medicine at Stanford Medicine and founding director of the Stanford Center for Cancer Cell Therapy.¹

Key facts

  • Company: Verismo Therapeutics (Philadelphia), a subsidiary of HLB Innovation
  • Licensed technology: PACK-IT in vivo CAR T engineering platform
  • Licensor: Stanford Medicine (laboratory of Crystal Mackall, MD)
  • Mechanism: T cell-targeted lentiviral particles deliver CAR genes to T cells
  • Intended use: Off-the-shelf, in vivo delivery of KIR-CAR T cell therapies
  • Platform: Multi-chain KIR-CAR (KIR plus DAP12 split signaling, NK cell-derived)
  • Clinical programs: SynKIR-110 (NCT05568680); SynKIR-310 (NCT06544265)
  • Indications studied: Mesothelin-expressing solid tumors; relapsed/refractory B-NHL
  • Stage: Both candidates in phase 1; PACK-IT application preclinical
  • Deal terms: Not disclosed

“Today, KIR-CAR is advancing along the established CAR T pathway in two [p]hase 1 clinical trials, and adding the PACK-IT technology is intended to extend the platform into next-generation, off-the-shelf in vivo delivery,” said Bryan Kim, CEO and cofounder of Verismo Therapeutics, in a company press release.¹

What does the PACK-IT technology do?

The PACK-IT platform uses engineered T cell-targeted lentiviral particles to deliver CAR genes directly to T cells.¹ It can be deployed in vivo, to reprogram a patient's own T cells in the body, or ex vivo in an accelerated workflow.¹ Stanford described the particles as carrying modified envelope proteins with antibodies that bind T cell surface receptors and direct viral entry, delivering the CAR gene without the usual activation and expansion steps.²

In preclinical data presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, PACK-IT generated CAR T cells with greater potency than conventional lentivirus. It also enabled in vivo generation of CD19-directed CAR T cells that controlled leukemia in preclinical models.¹,³

Why pursue in vivo CAR T engineering?

Approved CAR-T therapies are made ex vivo, a personalized process in which each patient's cells are collected, engineered, expanded, and quality tested in a facility over several weeks before being returned to the patient.¹ Verismo said that process has enabled the current generation of approved therapies, but its complexity can limit patient access and raise cost.¹ The company intends to apply PACK-IT primarily in an off-the-shelf, in vivo configuration, compressing the multi-week workflow into a same-day in vivo step.¹

How does the KIR-CAR platform differ from conventional CAR T?

KIR-CAR uses a multi-chain, split-signaling architecture derived from natural killer cells.¹ It pairs a KIR with DAP12 to separate target binding from T cell activation, giving a paired immune-receptor activation that is independent of CD3 signaling and does not require co-stimulation.¹ Verismo said the design is intended to eliminate the constant background activation and early T cell exhaustion seen with conventional single-chain CAR-T therapy.¹

What is in the clinic now?

Two KIR-CAR candidates manufactured ex vivo are in phase 1 trials: SynKIR-110 (NCT05568680) in mesothelin-expressing ovarian cancer, cholangiocarcinoma, and mesothelioma, and SynKIR-310 (NCT06544265) in relapsed or refractory B-cell non-Hodgkin lymphoma.¹,⁴ According to Verismo, initial STAR-101 data for SynKIR-110 presented at AACR 2026 showed a positive safety profile with dose-dependent efficacy signals and no dose-limiting toxicities. Initial CELESTIAL-301 data for SynKIR-310 included a complete response in a patient with follicular lymphoma at the lowest dose level, sustained beyond 6 months.¹

What are the limitations?

The release does not disclose financial terms of the license, a development timeline, or which KIR-CAR constructs will be paired with PACK-IT. PACK-IT data are preclinical and were presented in a conference abstract rather than a peer-reviewed journal, and Stanford's technology listing describes the platform as preclinical with in vivo work in progress.² The clinical results described are early phase 1 findings in small numbers of patients, reported by the company and not yet peer reviewed. No in vivo KIR-CAR candidate has entered clinical testing.

References

  1. Verismo Therapeutics. Verismo Therapeutics licenses in vivo CAR T engineering technology to extend its novel multi-chain KIR-CAR platform. Press release. Published November 18, 2026. Accessed November 18, 2026. https://prnmedia.prnewswire.com/news-releases/verismo-therapeutics-licenses-in-vivo-car-t-engineering-technology-to-extend-its-novel-multi-chain-kir-car-platform-302943157.html
  2. Stanford University. Rapid, programmable CAR-T cell engineering platform using antigen-targeted lentiviral particles. Docket S25-016. Accessed November 18, 2026. https://techfinder.stanford.edu/technology/rapid-programmable-car-t-cell-engineering-platform-using-antigen-targeted-lentiviral
  3. Burdsall KA, Xu P, Castro-Martinez D, et al. Abstract LB091: T cell targeted lentiviral gene delivery using the PACK-IT platform generates CAR-T cells with superior potency compared to conventional lentivirus and enables in vivo generation of CD19-CAR T cells capable of controlling leukemia in preclinical models. Cancer Res. 2025;85(8_Suppl_2):LB091. doi:10.1158/1538-7445.AM2025-LB091
  4. SynKIR-110 for mesothelin expressing ovarian cancer, cholangiocarcinoma or mesothelioma. ClinicalTrials.gov; NCT05568680. Updated June 24, 2026. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT05568680

Related to this article